The Company reports unaudited total revenue of US$114.9M1 (AU$175.0M) an increase of 18% on
the prior quarter (US$97.1M2 or AU$148.1M). Revenue was primarily generated from sales of Telix’s
prostate cancer imaging product Illuccix®.
U.S. revenue grew by 18% to US$111.8M (US$95.1M in Q4 2023), compared to 11% growth
between Q3 2023 and Q4 2023.
Ann: Telix Q1 2024 Revenue and Business Update, page-2
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.110(0.61%) |
Mkt cap ! $6.141B | |||
| Open | High | Low | Value | Volume |
| $18.55 | $19.06 | $17.87 | $18.29M | 995.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 644 | $17.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.00 | 1256 | 15 |
View Market Depth
| Last trade - 12.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$18.01 |
Change
0.110 ( 0.95 %) |
||||
| Open | High | Low | Volume | ||
| $18.59 | $19.06 | $17.88 | 179009 | ||
| Last updated 12.28pm 06/06/2024 ? | |||||
| TLX (ASX) Chart |